Products for Research Use Only
RegisterLogin

BX471

CAT: 0804-HY-12080-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12080-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BX471 (ZK-811752) is an orally active, potent and selective non-peptide CCR1 antagonist with a Ki of 1 nM, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.
CAS Number
217645-70-0
Product Name Alternative
ZK-811752
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
CCR
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Endocrinology
Assay Protocol
https://www.medchemexpress.com/BX471.html
Concentration
10mM
Purity
99.98
Solubility
DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL (ultrasonic)
Smiles
O=C(N)NC1=CC(Cl)=CC=C1OCC(N2[C@H](C)CN(CC3=CC=C(F)C=C3)CC2)=O
Molecular Formula
C21H24ClFN4O3
Molecular Weight
434.89
Precautions
H302, H315, H319, H335
References & Citations
[1]Liang M, et al. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem. 2000 Jun 23;275 (25) :19000-8.|[2]Anders HJ, et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest. 2002 Jan;109 (2) :251-9.|[3]Furuichi K, et al. Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury. J Immunol. 2008 Dec 15;181 (12) :8670-6.|[4]Horuk R, et al. A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J Biol Chem. 2001 Feb 9;276 (6) :4199-204.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CCR1
Citation 01
BioRxiv. 2024 November 03.|Cancer Lett. 2025 Sep 25:634:218064.|Cell Res. 2018 Mar;28 (3) :323-335. |Immunol Lett. 2018 Dec:204:29-37.|Int Immunopharmacol. 2025 Jan 12:147:114027.|Int J Mol Sci. 2024 Apr 14, 25 (8), 4337.|J Agric Food Chem. 2024 Apr 15.|J Inflamm Res. 2020 Jul 21;13:343-356.|Lab Invest. 2020 Apr;100 (4) :619-629.|Mol Med. 2024 Dec 20;30 (1) :253.|Mol Med. 2024 Jun 3;30 (1) :74.|Neuron. 2025 Nov 18:S0896-6273 (25) 00803-7.|Neuropharmacology. 2024 Nov 26:264:110239.|Proc Natl Acad Sci U S A. 2025 Aug 26;122 (34) :e2503779122.|Research Square Preprint. 2021 Oct.|Sci Adv. 2021 May 26;7 (22) :eabb5943.|Sci Rep. 2020 Nov 25;10 (1) :20508.|Cancer Cell. 2021 Mar 8;39 (3) :423-437.e7.|J Exp Clin Cancer Res. 2022 Mar 3;41 (1) :81.|J Invest Dermatol. 2025 Nov 28:S0022-202X (25) 03613-9.|Signal Transduct Target Ther. 2021 Feb 28;6 (1) :91.

Alternative Products

CatalogName
BUP07758-01BX471
NLA26296-01BX471 hydrochloride
A14409-100BX471 100mg
A14409-1BX471 1mg
A14409-200BX471 200mg
A14409-50BX471 50mg
A14409-25BX471 25mg

Popular Products